Clinical TrialMay 27, 2026, 08:12 AM
Ernexa Therapeutics ERNA-101 on track for Q3 2026 IND submission
AI Summary
Ernexa Therapeutics announced significant progress for its lead therapeutic candidate, ERNA-101, positioning it for an Investigational New Drug (IND) submission in the third quarter of 2026. The company successfully completed process development activities and transitioned into Good Manufacturing Practice (GMP) manufacturing in preparation for clinical development. This advancement, along with ongoing technology transfer, marks a critical step towards initiating its first-in-human clinical study and transforming Ernexa into a clinical-stage biotechnology company.
Key Highlights
- ERNA-101 IND submission targeted for Q3 2026.
- Process development for ERNA-101 manufacturing successfully completed.
- Transition to GMP manufacturing underway for clinical studies.
- Technology transfer activities for ERNA-101 are actively in progress.
- Company anticipates transformation into a clinical-stage biotechnology company.
- Progress supports planned first-in-human clinical study following IND clearance.
Price Impact
More from ERNA